severe manifestations in 6 of them; 3 patients suffered from euthyroid autoimmune thyroiditis from baseline, one after ipilimumab; 2 patients developed after transient thyrotoxicosis. Mean follow-up after anti-CTLA4 inhibitors treatment was 36 ± 28 months. Thyroid disorders occurred 45.1 ± 20.8 and 151 ± 67 days after the initiation of CTLA4 and PD1 inhibitors, respectively. Autoimmune disorders and BRAF mutation were associated with a better clinical response to CTLA4 followed by PD1 treatment. Conclusions Immune checkpoint blockade is burdened by a high incidence of autoimmune thyroid dysfunction, which is often severe. Therefore, early and careful monitoring and, eventually, treatment are crucial to prevent the negative impact of thyroid dysfunction on the clinical outcome.
Introduction
Monoclonal antibodies inhibiting the immune checkpoint inhibitors (ICI) CTLA4 (cytotoxic T-lymphocyte antigen-4) and PD1 (programmed cell death 1) are among the most promising therapeutic strategies for advanced solid tumors [1] .
ICI inhibitors are fundamental for maintaining self-tolerance, thus preventing autoimmunity, and modulating the duration and amplitude of the immune response to avoid tissue damage. Tumors can alter ICI expression to resist to the immune system, particularly against T cells that play a pivotal role in the anti-tumor response. ICI-blocking antibodies target tumor cells indirectly by binding to lymphocyte receptors or their ligands, and thus enhancing endogenous antitumour activity [2] .
3
CTLA4 is expressed only on T cells and regulates the amplitude of the early stages of T cell activation. After antigen recognition, CD28 signaling strongly amplifies TCR signaling to activate T cells. It has been postulated that CTLA4 outcompetes CD28 by binding to the same receptors (CD80 and CD86), and by sending inhibitory signals directly to T cells (still under investigation). CTLA4 mainly acts on CD4+ T cells by downregulating helper T cells, and enhancing the immunosuppressive activity of regulatory T cells [2] .
On the contrary, the role of PD1 is to limit T-cell activity in peripheral tissues during inflammatory responses and to prevent autoimmunity. It is expressed only after T-cell activation and inhibits kinases involved in T-cell activation through various signaling pathways. Like CTLA4, PD1 is highly expressed on TReg cells that often infiltrate tumors and suppress effector immune responses. Therefore, the blockade of PD1 may enhance antitumor immune response also by reducing the number and/or inhibit TRegs. PD1 is also expressed on activated B and NK cells, limiting antibody production and lytic activity, respectively. These activities are enhanced by PD blockade. Moreover, PD1 blockade partially reverses the state of anergy of cognate antigenspecific T cells associated with persistent PD1 expression induced by chronic antigenic exposure in cancer [2] . Therefore, CTL4 regulates T-cell activity at an early stage by limiting the initiation of a T-cell response to self-antigens in lymph nodes and preventing autoimmunity, while PD1 regulates later effector T-cell activity within tumor microenvironment [2, 3] .
Based on the evidence of survival benefit, ipilimumab (a monoclonal IgG1κ anti-CTLA4 antibody), nivolumab and pembrolizumab (IgG4 anti-PD1 monoclonal antibodies) have been authorized for the treatment of advanced melanoma [4] [5] [6] . Since CTLA4 and PD1 regulate immune responses at different levels and by different mechanisms, they have been more recently approved for sequential and combination therapy [4] [5] [6] .
On the other hand, pathognomonic and expected side effect of these drugs is the induction of immune-related adverse events (IRAEs) [3, 7] . Thyroiditis is the most common endocrine IRAE in patients treated with PD1 inhibitors and the second most common in those treated with anti-CTLA4 antibodies. Thyroiditis often manifests with severe hypothyroidism, while autoimmune hyperthyroidism is less common [8, 9] . The combination of CTLA4 and PD1 inhibitors further improves tumor control and progressionfree survival, although burdened by an increased risk of side effects, especially thyroid dysfunction [9] .
Based on these premises, the aim of our prospective single-arm study was to assess the prevalence, type, severity and time of onset of primary thyroid disorders in patients treated with CTLA4 and PD1 inhibitors for advanced melanoma. [10] ), in progression after treatment with standard chemotherapy and eligible for CTLA4 inhibitors, were enrolled in the study.
Materials and methods

Fifty
The sample included 30 females and 22 males; mean age was 65 ± 13 years (range 35-86). Patients had been previously treated, in variable combination, with standard chemotherapy (i.e., dacarbazine, cisplatin and temozolomide) or chemo-immunotherapy (i.e., IFN α-2b) and/ or target therapy (i.e., anti-BRAF-MEK inhibitors). Fifteen patients (28.8%) presented a BRAF gene mutation ( Table 1) .
All patients received 4 doses of ipilimumab, (Yervoy ® , Bristol-Myers Squibb, 3 mg/kg i.v. every 3 weeks, in accordance with manufacturer-approved guidelines). In case of disease progression, further treatment was defined on the basis of drug availability at that time as per clinical protocols or practice (Table 2) . Twenty-nine patients were allocated to treatment with PD1 inhibitors (14 received nivolumab, Opdivo ® , Bristol-Myers Squibb, 3 mg/kg i.v. every 2 weeks; 15 were treated with pembrolizumab, Keytruda ® , Merck Sharp & Dohme Corp., 2 mg/kg i.v. every 3 weeks). Indications to continue or discontinue PD1 treatment were re-defined periodically, based on radiologically assessed oncological response and side effects. Treatment with PD1 inhibitors was started after a wash out period of 15.4 ± 11.7 months (range 2.9-44.8) from the end of the treatment with CTLA4 inhibitors (Table 1 ). Response to treatment was defined according to immune-related response criteria [11] .
According to the study protocol, all patients were evaluated for thyroid function and presence of anti-thyroid antibodies (anti-thyroglobuline, ab-TG, and anti-thyroperoxidase, ab-TPO, antibodies) before starting, after 6 weeks and at the end of CTLA4 treatment. Patients allocated to PD1 inhibitors were also evaluated at the beginning, then every 3 months during the treatment period. Further evaluations were performed in case of symptoms suggestive for thyroid dysfunction. Thyroid ultrasound was performed in case of biochemical alterations suggestive for thyroid dysfunction. Hypothyroidism was defined as elevated TSH (> 4.20 mcUI/ml) levels with normal (subclinical form), or decreased (overt form) free thyroid fractions. On the other hand, thyrotoxicosis was defined as suppressed TSH levels (TSH < 0.05 mcUI/ml) with normal (subclinical form), or increased (overt form) free thyroid fractions. Autoimmune etiology was defined based on positive autoantibodies and/ or ultrasound findings. Complete response (n; %) - Informed consent was obtained from all individual participants included in the study that was approved by the Hospital Ethics Committee.
Statistical analysis
Continuous variables were expressed as mean ± standard deviation (SD), categorical variables as frequencies and percentages. Student's t test was used to compare the mean values in patients treated with CTL4 followed by PD1 vs. CTLA only for continuous variables. Fisher's or Chi-square test was used to investigate differences between dichotomous variables. Correlation analysis and univariate analysis were performed to assess possible predictors (i.e., previous drugs known to affect thyroid function, or BRAF gene mutation) of new onset thyroid disorders after CTLA4 and PD1 treatment. A Wilcoxon rank sum test was used to test differences between non parametric samples. Monovariate logistic regression analysis was performed to test the possible association between the new onset of autoimmune disorders or BRAF mutation with the clinical outcome after treatment. A p value < 0.05 was considered statistically significant. All statistical analyses were performed using Stata Statistical Software release 11 (StataCorp 2009; College Station, TX, USA).
Results
The group of patients treated with anti-CTLA4 only, and the group treated with anti-CTLA4 followed by anti-PD1 antibodies were homogeneous for gender (females 52.2 vs. 62.1%, p = 0.58) and age at anti-CTLA4 antibodies treatment start (67 ± 12 vs. 64 ± 14 years, p = 0.25) ( Table 1) .
The mean clinical follow-up after the conclusion of treatment with CTLA4 inhibitors was 36 ± 28 months (range 1-105), significantly longer in patients treated with anti-CTLA4 followed by anti-PD1 antibodies than in those treated with anti-CTLA4 antibodies only (57 ± 19 vs. 8 ± 8 months; p < 0.001), because of the longer mean survival rate in the first group of patients. Nineteen (82.6%) patients treated with CTL4 only, and 12 (42.4%) treated with CTLA4 followed by PD1 inhibitors died for disease progression (p = 0.57) ( Table 1 ). The best response achieved with CTLA and PD1 treatment, and patient conditions at last follow-up are detailed in Table 1 .
At baseline, 15 patients (28.8%; F:M = 12:3) presented with thyroid alterations: 6 with autoimmune hypothyroidism (one associated with multinodular goiter, MNG), 3 with normal functioning autoimmune thyroiditis (2 associated with MNG), 4 with thyrotoxicosis (3 associated with MNG), and 2 with post-thyroidectomy hypothyroidism (Table 3 ). Nine out of 15 (60%) patients were positive for anti-thyroid autoantibodies. Following treatment with CTLA4, 7 other patients (F:M = 4:3) presented with new onset/worsening of thyroid dysfunction, including a new case of autoimmune hypothyroidism, 3 cases of normal functioning autoimmune thyroiditis, and 2 of thyrotoxicosis in previously euthyroid MNG, while replacement therapy with l-thyroxine, previously associated with adequate thyroid substitution, became insufficient in another patient (Table 3 ). Five out of seven patients developed anti-thyroid autoantibodies. Overall, at the end of treatment, 22/52 (42.3%) patients presented with thyroid abnormalities.
Before starting PD1 inhibitors, 14 out 29 patients (48.3%) presented with thyroid impairment that could have developed before or after treatment with CTLA4 inhibitors. Treatment with PD1 inhibitors was associated with the occurrence of 7 new cases (24.1%; F:M = 3:4) of hypothyroidism. Four out of 7 patients presented normal thyroid function with negative autoantibodies at baseline and after CTLA4 inhibitors, while one had developed euthyroid autoimmune thyroiditis during the treatment. The other 3 patients had been diagnosed with euthyroid autoimmune thyroiditis before the beginning of treatment with CTLA4 inhibitors (Table 4 ). In these patients thyroid function was not affected by treatment. Six out of 7 cases presented with severe biochemical and clinical manifestations; in 2 cases, hypothyroidism occurred after a short period of transient thyrotoxicosis.
At the end of treatment, 21 out of 29 (72.4%) patients presented with thyroid abnormalities. Thyroid disorders occurred after a mean of 45.1 ± 20.8 days after the initiation of CTLA4 inhibitors, and 151 ± 67 days for PD1 (mean Table 3 With regards to the prevalence of extra-thyroid autoimmune diseases, 2 patients presented with celiac disease, and 1 with ulcerous colitis associated with vitiligo at baseline. During treatment with CTLA4 inhibitors, we registered 3 new cases of vitiligo, 1 of psoriasis, 1 of alopecia areata and 3 of autoimmune enteropathy; the case of ulcerous colitis diagnosed before treatment worsened with ipilimumab. Only one patient developed an autoimmune enthesopathy during treatment with PD1 inhibitors (Table 5) .
The presence of BRAF gene mutation or extra-thyroid autoimmune diseases (in 15 out of 52 patients, 28.8%) did not appear risk factors for the development of thyroid disorders after treatment with immune checkpoint inhibitors (p = 0.47). On the other hand, multivariate logistic regression test demonstrated an association between the new occurrence of autoimmune thyroid/extra-thyroid disorders and a better response to anti-PD1 treatment (OR = 6.99, p = 0.04). The presence of BRAF mutation was associated with a better clinical response to treatment with PD1 inhibitors (OR = 10.7, p = 0.04).
Occurrence of autoimmune thyroid and extra-thyroid disorders is associated with a better response to treatment to PD1 inhibitors.
Discussion
Our study demonstrates a significant risk of developing thyroiditis, particularly severe hypothyroidism, in patients treated with immune checkpoint inhibitors for advanced melanoma. Since the FDA approval of ipilimumab in 2010, immune checkpoint inhibitors have increasingly been used in patients with advanced melanoma for the impressive improvement in survival rate, while the therapeutic indications to the different drugs have changed over the years. During the time frame of patient enrollment in this study, patients with progressing disease after standard treatment could be allocated to ipilimumab then to PD1 inhibitors, while in the subsequent years, CTLA4 and PD1 inhibitors have been authorized as first-line treatment for advanced melanoma.
On the other hand, treatment with immune checkpoint inhibitors significantly increases the risk of inflammatory and autoimmune disorders, typically affecting skin, the gastrointestinal and the endocrine systems, i.e., pituitary and thyroid [3] .
The overall incidence of thyroid disorders in our patients treated with CTLA4 inhibitors (13.5%) and with CTLA4 followed by PD1 inhibitors (24.1%) is in line with literature. According to a metanalysis by Abdel-Rahman et al. performed on 3278 patients with solid tumors treated with CTLA4 or PD1 inhibitors in phase II-III randomized controlled trials, the relative risk associated with immune checkpoint inhibitors versus controls was 8.26 (4.67-14.62) for all-grade hypothyroidism, and 5.48 (1.33-22.53) for hyperthyroidism, with no significant differences related to the type and dose of treatment, or underlying cancer diagnosis [8] . A subsequent metanalysis by Costa et al. including 2148 patients, found an absolute risk of 6.52% to develop hypothyroidism and of 3.03% of hyperthyroidism in patients with advanced stage solid tumors treated with anti-PD1 (3205 patients), as well as a mean RR of 3.44 for hyperthyroidism, and a 6.79 for hypothyroidism when compared to patients treated with standard non-anti-PD1 therapy [12] . A systematic review of 251 cases treated with ipilimumab, nivolumab or pembrolizumab for advanced tumors, reported the occurrence of hypothyroidism in 1.7, 10 and 28.6% of the cases, respectively, while hyperthyroidism was reported in only 1.7% of the patients treated with ipilimumab [4] . Based on the results of large trials, the incidence of thyroid disorders associated with anti-PD1 antibodies appeared higher, as compared with ipilimumab [9] . The risk of thyroid dysfunction, especially of high grade, also increases when patients are treated with a combination of ipilimumab and nivolumab [3, 9] . De Filette et al. demonstrated, in patients with melanoma treated sequentially with ipilimumab and nivolumab, a higher risk of thyroid dysfunction associated with a wash out period < 4 weeks [13] .
Thyroid disorders occurred after a mean of 45.1 ± 20.8 days from the initiation of CTLA4 inhibitors, which is in line with literature, reporting the onset of most of the cases after 2-4 months, although they can be detected since the 1st week and up to some months after treatment discontinuation [3, 9] . On the other hand, thyroid alterations associated with PD1 seemed to occur later (mean 151 ± 67 days after treatment start). This observationalthough difficult to be compared with literature, since time of disease onset is missing in most of the studies-could be secondary to the different mechanisms and timing of intervention in the immune response exerted by CTLA4 and PD1. Indeed, CTLA4-pathway modulates the early-phase activation with subsequent repression on naïve memory T cells, while PD1 modulates the peripheral activity of T cells during active inflammatory processer, so limiting autoimmunity in conditions with persistent antigen stimulation [2, 3, 14] .
All patients presenting with thyroid disorders were managed with medical treatment, performed according to international guidelines addressing thyroid disorders in the general population [15, 16] and in patients developing Graves' disease after immune reconstitution associated with therapy (i.e., monoclonal antibodies, antiretroviral therapy, bone marrow/hematopoietic stem cell transplantation) [17] , due to the absence of specific indications in patients treated with immune checkpoint inhibitors. In none of the cases, CTLA4 or PD1 had to be interrupted.
In patients treated with PD1 inhibitors, hypothyroidism was often preceded by a short-lasting, transient thyrotoxicosis, which is in agreement with the observations of Alhusseini et al. [18] , and, differently from the general population in which autoimmune thyroid disorders show a net female predominance [19] , males and females were equally affected.
The high prevalence of severe hypothyroidism associated with PD1 vs. CTLA4 inhibitors detected in our patients could result from the addictive immunomodulatory effect of sequential treatment, but also from the involvement of different molecular mechanisms [2] . Indeed, the exact pathogenesis of thyroid dysfunction associated with blockade of immune checkpoint inhibitors, as well as the reasons underlying thyroid predilection, remains to be elucidated. The immune stimulation associated with these drugs, the detection of thyroid autoantibodies in some patients, as well as the co-occurrence of extra-thyroid autoimmune disorders observed in our and in previous studies suggest an autoimmune etiology [9, 13] , although not supported by histological observations. As for other IRAEs, thyroiditis could arise from a non-specific immune activation in patients with genetic predisposition, including CTLA4 and PD1 gene polymorphisms, although these results remain to be verified on larger scale [4, 9, 20] . It also remains to clarify if thyroid autoantibodies have a causative role or are just the consequence of thyroid damage, especially in case of PD1 treatment. Indeed, in autoimmune thyroiditis, the presence of autoantibodies well correlates with a T-cell thyroid infiltration, being patients positive for antiTPO antibodies at increased risk of hypothyroidism. Pembrolizumab is an IgG4 monoclonal antibody. Since this subclass of Igs is not associated with antibody-dependent or complementdependent cytotoxicity, an immune reaction triggered by its interaction with the PD1 receptor expressed in the thyroid is unlikely [13] . Very recently, Delivanis et al. [14] + monocytes, while the overall number remained stable in peripheral blood. Thus, pembrolizumab-induced thyroiditis could be secondary to monocyte activation through the upregulation od HLA-DR. Finally, surface expression of PD-1 was not detectable on T cells in patients treated with pembrolizumab, while it was similar between patients with autoimmune thyroiditis and healthy controls, suggesting the predominance od T-cell-mediated than antibody-mediated thyroid destruction [14] .
From a clinical point of view, the most important findings of our study is the frequent occurrence of severe hypothyroidism during treatment with immune checkpoint inhibitors, especially when anti-CTLA4 and PD1 are administered sequentially, for its potential impact on patient's quality of life, as well as compliance to the treatment and outcome. At the same time, symptoms associated with hypothyroidism could be difficult to be recognized in the early phase, and distinguished from those associated with the underlying neoplastic disease, or side effects of the antineoplastic treatment itself. Finally, thyroid dysfunction can rapidly occur and, apparently, cannot be predicted from patient characteristics (i.e., equally affect males and females), nor clinical history (i.e., previous treatments) or presence of thyroid autoantibodies. Therefore, a careful assessment of thyroid function and autoimmunity is strongly recommended at baseline and periodically during treatment, especially in patients undergoing sequential treatment with CTLA4 and PD1 inhibitors, since the chance of developing thyroid disorders during the second treatment is independent from the previous.
The study reflects the real-life experience of a single reference Institution. Other study's strengths are the homogeneity of the sample, the systematicity of evaluations, the prospective design, and the long-term follow-up. On the other hand, the fact that patients had received other treatments (in particular, IFN and IL2 known to affect thyroid function in some cases [8] ) before anti-CTLA4 and anti-PD1 could represent a bias for the definition of the risk of thyroid disorders associated with immune checkpoint inhibitors. Finally, our study confirmed the association between the development of IRAEs and a better clinical outcome after treatment with CTLA and PD1 identified by previous studies [21, 22] .
Conclusions
Treatment with CTL4 and PD1 inhibitors is associated with a high incidence of thyroid dysfunctions in both females and males, especially when these drugs are administered sequentially, and often manifest with severe hypothyroidism. Therefore, patients receiving immune checkpoint inhibitors, independently from the compound, dose and schedule deserve close monitoring of thyroid function and autoimmunity, especially during sequential immunotherapy, to avoid severe thyroid damage, which can negatively impact on the patient compliance to treatment and clinical outcome.
Patients receiving immune checkpoint inhibitors, independently from the compound and dose, deserve close monitoring of thyroid function and autoantibodies for the frequent development of alterations, mainly of autoimmune origin, that can rapidly occur and evolve from a determined functional picture to another. Larger prospective studies, directly comparing patients allocated to different types and regimens of immune checkpoint inhibitors as first-line treatment, are warranted to better characterize typical features and identify risk factors of thyroid dysfunction, as well as to define its impact on clinical outcome, aimed at a more patient-tailored management.
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